Classes
DEA Class; Rx
Common Brand Names; Rilutek, Tiglutik, Exservan
- Glutamate Inhibitors
Description
Oral glutamate antagonist
Used for treatment of amyotrophic lateral sclerosis (ALS)
Does not cure disease or improve symptoms, but may prolong survival by 3 months
Indications
Indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Contraindications
Hypersensitivity to drug or any component of the formulation
Adverse Effects
- Oral hypoesthesia (29%)
- Asthenia (19%)
- Nausea (16%)
- Decreased lung function (10%)
- Hypertension (5%)
- Abdominal pain (5%)
- Vomiting (4%)
- Arthralgia (4%)
- Dizziness (4%)
- Dry mouth (4%)
- Insomnia (4%)
- Pruritus (4%)
- Tachycardia (3%)
- Flatulence (3%)
- Increased cough (3%)
- Peripheral edema (3%)
- Urinary tract infection (3%)
- Circumoral paresthesia (2%)
- Somnolence (2%)
- Vertigo (2%)
- Eczema (2%)
- Acute hepatitis
- Icteric toxic hepatitis
- Renal tubular impairment
- Pancreatitis
Warnings
Cases of severe neutropenia (absolute neutrophil count <500/mm3) within first 2 months of treatment reported; advise patients to report febrile illnesses
Interstitial lung disease, including hypersensitivity pneumonitis, reported in patients receiving therapy; discontinue immediately if interstitial lung disease develops
Pregnancy and Lactation
There are no studies in pregnant women, and case reports have been inadequate to inform of drug-associated risk
Unknown if risk of major birth defects and miscarriage in patients with amyotrophic lateral sclerosis
Unknown if distributed in human breast milk
Maximum Dosage
100 mg/day PO for ALS; 200 mg/day PO off-label for Huntington’s Chorea.
100mg/day PO for ALS; 200 mg/day PO off-label for Huntington’s Chorea.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Riluzole
tablet
50mg
oral suspension
5mg/mL (300-mL multidose bottle)
oral film
50mg
